We determined the relationship between the intensity of CD20 expression and treatment response in patients with B-cell lymphomas. The CLL patients had a significantly lower CD20 expression than patients with other B-cell lymphomas. The cut-off value of CD20 expression was set at 25000 MESF. Patients with the CD20 expression above the cut-off value had a significantly higher overall response rate and a significantly longer overall survival than patients with the CD20 expression below the cut-off value. In the study, 17.5% had the level of CD20 expression below the cut-off value.
COBISS.SI-ID: 988283
This study was aimed at assessing the ability of tumor vaccine composed of C-class CpG ODNs and irradiated melanoma tumor cells B16F1 followed by two additional injections of CpG ODNs to induce the generation of a functional long-term memory response in experimental tumor model in mice (i.p. B16F1). We demonstrated that tumor vaccine followed by two additional injections of CpG ODNs induces a long-term immunity (duration at least 8 months) against aggressive B16F1 tumors.
COBISS.SI-ID: 995195
First 2000 patients were analyzed. Associations between the identification rate and technical, patient-, and tumor-related factors were evaluated. The identification rate was 97%. The success rate depended upon age, pathological tumor size, histology, year of accrual and method of detection. The sentinel node biopsy (SNB) was negative in 65% of patients. The SNB results were positive in 34% of the patients, including macrometastases in 63%, micrometastases in 25% and isolated tumor cells in 12%. We proved that SNB procedure is a highly effective procedure.
COBISS.SI-ID: 981115
We investigated the efficacy and safety of cetuximab combined with two different chemotherapy regimens in patients with unresectable metastatic colorectal cancer. Patients received either cetuximab, 5-fluorouracil, folinic acid and oxaliplatin or cetuximab, 5-fluorouracil, folinic acid and irinotecan. No significant differences were found between the two treatment arms regarding progression-free survival and overall survival. Patients with KRAS wild-type tumors demonstrated improved progression-free survival, response rate and overall survival compared to patients with KRAS mutated tumors.
COBISS.SI-ID: 954491
The authors conclude that there are no significant differences in the prevalence of HPV 16 and 18 infection with regard to the type of contraception method used in the patient.
COBISS.SI-ID: 3693887